Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SC formulary Coverage & PA …
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    BlueCross Total Prescription Drug Formulary — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This document is the BlueCross Total prescription drug formulary for BlueCross BlueShield of South Carolina describing covered drugs, restrictions (prior authorization, quantity limits, step therapy), tiered cost sharing, and how members and providers can request exceptions; it affects plan members and prescribing providers.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlueCross Total Prescription Drug Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date05/01/2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when a drug is marked PA to avoid claim denial.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    05/01/2026Formulary current as of
    monthlyFormulary updates
    5Drug tiers
    $400Deductible (Tiers 3-5)
    72hStandard exception timeframe

    Formulary Coverage & Restrictions

    Formulary Coverage and Restrictions

    Covered drugs on the formulary are subject to general rules, member protections, and exception processes.

    General formulary coverage: Drugs listed on the BlueCross Total formulary are generally covered when medically necessary, dispensed at a network pharmacy, and used in accordance with plan rules.

    Source: formulary description

    Circumstances permitting immediate formulary changes: The plan may add or remove drugs, change tiers, or add restrictions during the year in specific circumstances, including addition of a new generic or certain biosimilar versions, withdrawal of a drug from the market, or changes based on clinical guidelines; affected members will be notified as required.

    Immediate substitutions and withdrawal rules

    Member protections and temporary coverage: When a drug is removed or a new restriction applied, members taking that drug may request an exception; in some cases (first 90 days of membership, LTC residents, level-of-care transitions) a temporary supply or emergency supply may be provided while an exception or coverage determination is pursued.
    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlueCross Total Prescription Drug Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material changes
    Effective Date05/01/2026
    Last ReviewMay 1, 2026
    Next Review DateN/A
    Key ActionSubmit a prior authorization request when a drug is marked PA to avoid claim denial.
    SourceLink
    On This Page
    Formulary Coverage & RestrictionsFormulary Listings & CodesRequired Provider Actions, Prior Authorization & Denial RiskKey Terms & AbbreviationsStep Therapy Rules & Identified ProductsDocumented Quantity Limits (Selected Examples)Background & Scope

    Temporary supplies and exception process

    Formulary coverage indicators (partial)"

    Each formulary line shows tiering and may include Requirements/Limits flags that affect coverage.

    Line-item coverage indicators: Every product line includes a Drug Tier and may include Requirements/Limits flags such as PA (prior authorization), QL (quantity limit with exact amount and time period), NDS (document-specific flag), or ST/ST NSO (step therapy); coverage requires adherence to any flags shown for that product.

    See Requirements/Limits Key in formulary

    Examples of flags and application: Where QL is shown, the member’s dispensed quantity must not exceed the stated QL (e.g., QL(30 GM per 30 days) for lidocaine/prilocaine cream; QL(1800 ML per 28 days) for linezolid suspension). Where PA or PA NSO is shown, prior authorization must be obtained before coverage is approved.

    Examples drawn from listed entries

    Covered with conditions

    Coverage for individual drugs in this segment is conditional on meeting the specific Requirements/Limits listed on the formulary entry.

    Coverage subject to Requirements/Limits: A drug will be covered only if the prescriber/member meets any Requirements/Limits listed for that product, including obtaining prior authorization (PA) when indicated and not exceeding stated quantity limits (QL).

    Applies per-drug where PA or QL specified

    Manufacturer or presentation restrictions: Some entries limit coverage to specific manufacturer‑labeled products (for example, certain ADALIMUMAB-ADBM entries are limited to Boehringer Ingelheim labeled products) — coverage requires adherence to those product‑specific restrictions.

    Manufacturer‑label restrictions noted where shown

    Specialty and immunologic agents: Many high‑cost specialty, biologic, and immunoglobulin products are designated with PA and QL entries (e.g., SIGNIFOR, COSENTYX, DUPIXENT, STELARA, ORENCIA); prior authorization and the listed quantity limits must be satisfied for coverage to be approved.

    Specialty drug PA/QL examples

    If a drug is not listed on the BlueCross Total formulary and an exception is not approved, the plan will not provide coverage for that drug. Members or prescribers should first contact Customer Service to confirm coverage and, if coverage is not available, may either request a list of clinically similar covered alternatives to discuss with the prescriber or submit a formal exception request per the plan's exception process.

    Certain formulary entries are explicitly marked Not Covered within Tier 5 specialty slots and for some covered insulin line items. The formulary shows tiered cost sharing and indicates specific Tier 5 positions as Not Covered; providers should reference the formulary rows (and mail‑order/LTC notes) when assessing coverage and member cost sharing.

    The listing uses the flag NDS next to multiple opioid and related products in the Requirements/Limits column, but this excerpt does not provide a definition. The introduction pages of the full formulary must be consulted for the exact meaning and application of NDS in coverage or dispensing rules.

    The formulary table in this segment presents each product's Drug Tier and any Requirements/Limits flags (for example PA, QL(...), NDS, or PA NSO). This extract contains tier assignments and utilization‑management flags, but does not include full clinical coverage criteria or rationale — those are defined elsewhere in the formulary introduction and policy pages.

    No comprehensive exclusion list appears in these chunks. Where symbols or abbreviations (for example in the Requirements/Limits column) are used, providers should consult the formulary's introduction pages for definitions and for any explicit exclusions referenced there.

    Some formulary entries are restricted to specific manufacturer‑labeled products (for example certain ADALIMUMAB entries note Boehringer Ingelheim labeled products only). When such product‑label limitations are shown, coverage is limited to that manufacturer’s labeled presentation unless an exception is granted.

    This extract is a formulary table showing Drug Tiers and Requirements/Limits annotations; it does not include an explicit list of items designated as 'Not Medically Necessary' in these chunks. Coverage determinations are driven by the Requirements/Limits flags (e.g., PA, QL) and by exception decisions where applicable.

    Formulary Listings & Codes

    Requirements/Limits examplesmixed
    QL(30 EA per 90 days)Quantity limit for JOURNAVX TABLET 50MG
    QL(60 EA per 30 days)Quantity limit for celecoxib capsule
    QL(1000 GM per 30 days)Quantity limit for diclofenac sodium gel 1%
    QL(4 EA per 28 days)Quantity limit for buprenorphine patch weekly
    QL(20 EA per 30 days)Quantity limit for ketorolac tromethamine tablet 10mg
    QL(30 GM per 30 days)Quantity limit for lidocaine/prilocaine cream 2.5%/2.5%
    QL(150 GM per 30 days)Quantity limit for lidocaine ointment/premium lidocaine ointment 5%
    Formulary requirement flagsmixed
    NDSRequirement/Limit flag shown next to multiple opioid products (document lists 'NDS' adjacent to various opioid entries)
    Quantity limitsmixedCovered
    QL(1800 ML per 28 days)Quantity limit applied to linezolid suspension reconstituted 100mg/5ml
    QL(120 EA per 30 days)Quantity limit applied to vancomycin hydrochloride capsule 125mg
    QL(240 EA per 30 days)Quantity limit applied to vancomycin hydrochloride capsule 250mg
    Authorization flagsmixed
    PAPrior authorization required (flag appears adjacent to multiple products)
    NSONSO flag used with PA for select products (appears as 'PA NSO' in the formulary)
    Formulary listed drugs (excerpt)NDC|internal
    sulfadiazine tablet 500mgDrug Tier = 5
    sulfamethoxazole/trimethoprim ds tablet 800mg; 160mgDrug Tier = 1
    doxycycline hyclate capsule 100mg, 50mgDrug Tier = 2
    brivaracetam solution 10mg/mlDrug Tier = 4; Requirements/Limits = PA NSO
    BRIVIACT SOLUTION 10MG/MLDrug Tier = 5; Requirements/Limits = PA NSO
    EPIDIOLEX SOLUTION 100MG/MLDrug Tier = 5; Requirements/Limits = PA NSO
    FINTEPLA SOLUTION 2.2MG/MLDrug Tier = 5; Requirements/Limits = PA NSO
    NAYZILAM SOLUTION 5MG/0.1MLDrug Tier = 4; Requirements/Limits = QL(10 EA per 30 days)
    clonazepam odt tablet disintegrating 2mgDrug Tier = 4; Requirements/Limits = QL(300 EA per 30 days)
    clonazepam odt tablet disintegrating 0.125mg, 0.25mg, 0.5mg, 1mgDrug Tier = 4; Requirements/Limits = QL(90 EA per 30 days)
    1–10 of 19
    1/2
    Selected formulary entries (partial)mixed
    SIGNIFOR INJECTION 0.3MG/ML, 0.6MG/ML, 0.9MG/MLDrug Tier = 5; Requirements/Limits = QL(60 ML per 30 days); PA
    SOMAVERT INJECTION 10MG, 15MG, 20MG, 25MG, 30MGDrug Tier = 5; Requirements/Limits = PA
    TRELSTAR MIXJECT INJECTION 22.5MGDrug Tier = 4; Requirements/Limits = QL(1 EA per 168 days); PA NSO
    TRELSTAR MIXJECT INJECTION 11.25MGDrug Tier = 4; Requirements/Limits = QL(1 EA per 84 days); PA NSO
    Formulary entries and limits (selected examples)mixed
    COSENTYX (multiple presentations)Drug Tier = 5; Requirements/Limits = QL(10 ML per 28 days); PA
    DUPIXENT 200MG/1.14ML and 300MG/2MLDrug Tier = 5; Requirements/Limits = QL(4.56 ML per 28 days) for 200mg; QL(8 ML per 28 days) for 300mg; PA
    ORENCIA (various presentations)Drug Tier = 5; Requirements/Limits = QL varying by presentation (e.g., 4 ML per 28 days for 125mg); PA
    SKYRIZI (various presentations)Drug Tier = 5; Requirements/Limits = QL per presentation (e.g., 1 ML per 28 days, 1.2 ML per 56 days, 60 ML per 365 days); PA
    STELARA (130MG/26ML; 45MG/0.5ML)Drug Tier = 5; Requirements/Limits = QL(104 ML per 365 days) for 130mg; QL(3 ML per 84 days) for 45mg; PA
    TREMFYA (multiple presentations)Drug Tier = 5; Requirements/Limits = QL varies by presentation; PA
    XELJANZ (tablets and XR)Drug Tier = 5; Requirements/Limits = QL per presentation (e.g., 30 EA per 30 days XR; 60 EA per 30 days tablets); PA
    XOLAIR (multiple presentations)Drug Tier = 5; Requirements/Limits = QL per presentation (e.g., 1 ML per 28 days; 8 EA per 28 days); PA
    ADALIMUMAB-ADBM and ADALIMUMAB-AATY (many presentations)Drug Tier = 5; Requirements/Limits = QL per presentation (examples: 6 EA per 28 days; 2 EA per 28 days); PA; some entries limited to specific manufacturer labeled products
    Various vaccines (multiple entries)Various tiers; Requirements/Limits vary (e.g., ABRYSVO QL(1 EA per 252 days); AREXVY QL(1 EA per 999 days); MRESVIA QL(0.5 ML per 999 days))
    Quantity limits examples — sample per‑drug QL values
    JOURNAVXQL(30 EA per 90 days)
    celecoxib capsuleQL(60 EA per 30 days)
    diclofenac sodium gel 1%QL(1000 GM per 30 days)
    ketorolac tromethamine tablet 10mgQL(20 EA per 30 days)
    Cablivi (example)QL(30 EA per 30 days)
    Linezolid suspension limit
    linezolid suspension (100mg/5ml, reconstituted)QL(1800 ML per 28 days)
    linezolid tablet 600mgQL(56 EA per 28 days)
    related noteQuantity limit applies to reconstituted suspension form as listed in Requirements/Limits.
    Vancomycin 125mg capsule — quantity limit
    vancomycin hydrochloride capsule 125mgQL(120 EA per 30 days)
    vancomycin injection (examples)Requirements/Limits show injections separately (no capsule QL)
    tierDrug Tier = 4 (capsules listed under Tier 4)
    Vancomycin 250mg capsule — quantity limit
    vancomycin hydrochloride capsule 250mgQL(240 EA per 30 days)
    alternate formsVancomycin injection products listed separately without same QL
    tierDrug Tier = 4 (250mg capsules listed under Tier 4)
    Quantity limits examples — multiple QL examples
    NAYZILAM solution 5mg/0.1mlQL(10 EA per 30 days)
    clonazepam tablet 2mgQL(300 EA per 30 days)
    VALTOCO (various liquid packs)QL(10 EA per 30 days)
    gabapentin solution 250mg/5mlQL(2160 ML per 30 days)
    EXXUA (selected strengths)QL(30 EA per 30 days) or QL(56 EA per 365 days) as listed
    Quantity Limits examples — QL(120 EA per 30 days), QL(60 EA per 30 days), etc.
    desvenlafaxine ER 25mg,50mgQL(30 EA per 30 days)
    DRIZALMA sprinkle capsule 20,60mgQL(60 EA per 30 days)
    ondansetron HCl solution 4mg/5mlQL(450 ML per 30 days)
    Quantity limits examples — assorted QL entries
    selected oncology agentsExamples show QL(60 EA per 30 days); QL(120 EA per 30 days); QL(30 EA per 30 days)
    PA NSO flag examplesMany molecular target and oncology agents include PA NSO with QL values
    ZEJULA 100mgQL(30 EA per 30 days) (see oncology entries)
    Quantity Limits (examples) — clozapine, others
    clozapine tablets and ODT formulationsExample QLs listed (e.g., QL(120 EA per 30 days) up to QL(540 ML per 30 days) for suspension)
    VERSACLOZ suspension 50mg/mlQL(540 ML per 30 days)
    INBRIJA / RYTARY examplesEntries include ST or QL flags (see table for per‑product QLs)
    Examples of quantity limits — assorted injectables and tablets
    dabigatran etexilate capsuleQL(60 EA per 30 days)
    ELIQUIS formulationsVarious QLs shown (e.g., QL(148 EA per 365 days); QL(84 EA per 28 days))
    MOUNJARO injectionQL(2 ML per 28 days)
    Examples of quantity limits — QL samples across sections
    PRALUENT injection 150mg/ml,75mg/mlQL(2 ML per 28 days)
    REPATHA presentationsQL(3 ML or 7 ML per 28 days depending on presentation)
    amphetamine/dextroamphetamine ER capsulesQL(60 EA per 30 days) or QL(90 EA per 30 days)
    diclofenac sodium gel 3% (topical)QL(300 GM per 30 days)
    Quantity limits examples — topical and liquid examples
    fluocinonide cream 0.1%QL(120 GM per 30 days)
    fluocinonide cream 0.05%QL(60 GM per 30 days)
    imiquimod cream 5%QL(48 EA per 30 days)
    Common QLs shown — contraceptives and others
    ethynodiol/ethinyl estradiol tablet exampleQL(1 EA per 90 days)
    oral contraceptives (multiple brands)QL(91 EA per 91 days)
    LOKELMA packetQL(90 EA per 30 days)
    Quantity limits examples — SIGNIFOR, TRELSTAR, STELARA examples
    SIGNIFOR injection (0.3/0.6/0.9 mg/ml)QL(60 ML per 30 days)
    TRELSTAR MIXJECT injection 22.5mgQL(1 EA per 168 days)
    STELARA injection 130mg/26mlQL(104 ML per 365 days)

    Required Provider Actions, Prior Authorization & Denial Risk

    Prior Authorization

    Prior Authorization Required — Provider Responsibilities

    Certain drugs in this formulary require prior authorization (PA), and many have quantity limits (QL) or step therapy (ST) requirements. Providers must submit a PA request when the Requirements/Limits column shows PA or PA NSO; failure to obtain required PA may result in claim denial. Quantity limits shown (e.g., QL(30 EA per 30 days)) must be followed unless an approved exception is granted. Step therapy flags (ST, ST NSO) indicate that specified first-line agents must be tried before coverage of alternate therapies.

    • Prior Authorization (PA) indicated for many products — submit PA before dispensing when PA or PA NSO appears in Requirements/Limits.
    • Quantity Limits (QL) are enforced as listed (examples throughout the table such as QL(30 EA per 30 days)); documentation is required to exceed limits or request exceptions.
    • Step Therapy (ST or ST NSO) appears for select agents (e.g., RYTARY = ST; AUVELITY, EXXUA, FETZIMA show ST or ST NSO); follow the step sequence where indicated.
    • PA NSO = Prior Authorization for New Starts Only or specialty review flags — apply per the Requirements/Limits note.
    • Refer to the introduction pages for symbol/abbreviation definitions and the formulary metadata (Formulary ID, Version, Effective Date, Last Updated) when interpreting table entries.
    Prior Authorization

    Anticonvulsants & Specialty Agents — PA / QL

    Selected anticonvulsants and specialty neurologic agents require PA or PA NSO; quantity limits apply to some anticonvulsants (e.g., NAYZILAM QL(10 EA per 30 days), clonazepam QL entries, gabapentin QLs). Examples: BRIVIACT and EPIDIOLEX are listed as PA NSO; FINTEPLA and DIACOMIT show PA NSO.

    • Brivaracetam (BRIVIACT) — PA NSO for tablets and solution.
    • EPIDIOLEX solution — PA NSO.
    • FINTEPLA solution — PA NSO.
    • DIACOMIT (stiripentol) — PA NSO; follow specialty PA procedures.
    • Clonazepam, gabapentin and NAYZILAM have stated quantity limits that must be adhered to or justified in PA/exception requests.
    Prior Authorization

    Oncology & Specialty Biologics — PA NSO / QL

    Many specialty, oncology, biologic and high-cost agents are designated PA NSO or PA with specific QLs. Providers must follow PA submission rules and include supporting clinical documentation. Examples include multiple molecular-targeted therapies and monoclonal antibodies listed with PA NSO.

    • Molecular target inhibitors and many oncology drugs (e.g., ALECENSA, BRUKINSA, VENCLEXTA, VERZENIO) — PA NSO.
    • Monoclonal antibodies/ADCs and other specialty oncology therapies — PA NSO; follow specialty pharmacy or network-site-of-care guidance if applicable.
    • Some oncology agents also carry quantity limits alongside PA NSO (see QL entries where present).
    Prior Authorization

    Cardiovascular & Metabolic Agents — PA / QL Examples

    Several cardiovascular, metabolic and specialty injectables/tablets require PA and/or have QLs. Examples include metyrosine (PA), sacubitril/valsartan (ENTRESTO) with QL, PCSK9 inhibitors with QL and PA, and KERENDIA with QL/PA. Claims exceeding QL or lacking PA risk denial.

    • Metyrosine 250 mg capsule — PA required.
    • ENTRESTO (sacubitril/valsartan) — QL(240 EA per 30 days); document when requesting exceptions.
    • PCSK9 agents (PRALUENT, REPATHA) — QL and PA apply (e.g., PRALUENT QL(2 ML per 28 days); PA).
    • KERENDIA — QL(30 EA per 30 days); PA required.
    • VERQUVO, NEXLETOL/NEXLIZET and other CV agents listed carry QL and PA as indicated.
    Prior Authorization

    Depot & Specialty Injections — PA / PA NSO

    Select depot and specialty injections require PA NSO or PA and often have quantity limits. Providers should confirm whether PA NSO (new-starts only) applies and follow site-of-care instructions.

    • Depot gonadotropin-releasing hormone agents (LUPRON DEPOT, FIRMAGON) — PA NSO; QL entries for 1-, 3-, 4-, 6-month formulations.
    • Leuprolide acetate and other depot injections — PA NSO or PA; check QL (e.g., LUPRON DEPOT QL per dosing interval).
    • Follow specialty injection PA procedures and provide required supportive clinical documentation.
    Prior Authorization

    Immunologic & Specialty Therapies — PA / QL

    Many immunologic and specialty immunoglobulin agents require PA and may carry QLs (e.g., PRIVIGEN, CINRYZE, BIVIGAM, BENLYSTA, DUPIXENT, ORENCIA, SKYRIZI). Submit PA with complete documentation to avoid denials.

    • Immunoglobulins (PRIVIGEN, GAMASTAN, BIVIGAM, HIZENTRA) — PA required; some products list QLs.
    • Biologics and immunologic agents (BENLYSTA, DUPIXENT, ORENCIA, COSENTYX, SKYRIZI) — QL and PA often apply; follow formulary Requirements/Limits.
    • Immunosuppressants and adalimumab biosimilars — QL and PA noted; some entries reference manufacturer labeling requirements (e.g., Boehringer Ingelheim labeled products only).
    Documentation Required

    Documentation & Exception Requests — What to Submit

    When PA or QL is indicated, providers must submit supporting clinical documentation with the PA request. Documentation should explain the medical necessity, prior therapies tried (if step therapy applies), and any reason for exceeding QL. Exception requests follow standard timelines: 72 hours for routine decisions and 24 hours for expedited requests when delay could seriously harm the patient.

    • Include prescriber's supporting statement and relevant medical records or rationale when requesting an exception or PA.
    • Routine exception decisions are made within 72 hours of receiving the prescriber's supporting statement; expedited requests are decided within 24 hours when appropriate.
    • Submit documentation to justify prior use of step-therapy alternatives or to request a waiver of QLs or PA requirements.
    Note

    How to Interpret Requirements/Limits & Formulary Metadata

    Follow the Requirements/Limits field for each drug entry. Use the introduction pages for symbol and abbreviation definitions (e.g., PA, PA NSO, QL, NDS, ST, ST NSO) and check the formulary metadata (Formulary ID, Version, Effective Date, Last Updated) when referencing coverage rules.

    • Submit prior authorization when the table shows PA or PA NSO; PA NSO may restrict coverage for new starts only.
    • Interpret table symbols using the introduction pages — this avoids misinterpretation of NDS, B/D, ST NSO and similar flags.
    • Formulary metadata: Formulary ID 26216, Version 13, Effective Date 06/01/2026; Last Updated 05/01/2026 (use these when citing formulary status).
    Denial Risk

    Denial Risk — Common Triggers

    Denial risk is triggered when required prior authorization is not obtained, quantity limits are exceeded without approval, or step therapy requirements are not met. Specialty/PA NSO designations and noncompliant site-of-care or manufacturer restrictions may also lead to denial.

    • Claims submitted without required PA or with QL exceedances may be denied — obtain PA or submit an exception request prior to dispensing.
    • PA NSO and site-of-care restrictions (NSO) can result in noncoverage for new starts if PA NSO conditions are not satisfied.
    • Manufacturer/label restrictions (e.g., Boehringer Ingelheim labeled products only) and failure to follow specialty program rules increase denial risk.

    Key Terms & Abbreviations

    Generic drug — definition
    Generic drugFDA‑approved drug with the same active ingredient as the brand name drug; generally substitutable per state law
    SubstitutionGeneric drugs usually can be substituted for brand name drugs at the pharmacy without a new prescription, depending on state law
    Cost noteGenerics generally cost less than brand name drugs
    Biologicals / Biosimilars — definition and interchangeability note
    Biological productA complex drug product; has biosimilar alternatives rather than generics
    BiosimilarAn alternative to the original biological product that generally performs similarly and may cost less
    InterchangeabilitySome biosimilars are interchangeable and may be substituted per state law without a new prescription
    PA abbreviation — Prior Authorization
    PAPrior Authorization — approval required from the plan before dispensing when indicated
    PurposePrevent noncovered or inappropriate use; failure to obtain may result in noncoverage
    How to checkSee Requirements/Limits column in formulary for 'PA' designation
    QL abbreviation — Quantity Limits
    QLQuantity Limits — maximum quantity the plan will cover in a specified time period (format: QL(...))
    PurposeLimits dispensed amount per period (e.g., per 30 days, per 28 days, per 365 days)
    Where shownDisplayed in Requirements/Limits column next to product entries
    NDS abbreviation — Non‑Extended Day Supply
    NDSNon-Extended Day Supply — item is not available for extended days' supply (NDS)
    ImplicationMay restrict dispensing to standard supply intervals rather than mail‑order/extended fills
    Where usedSeen adjacent to certain opioid and controlled formulations in Requirements/Limits
    ST abbreviation — Step Therapy
    STStep Therapy — trial of preferred agent(s) required before covering specified alternative
    ST NSOST NSO indicates step therapy for new starts only (as used in table)
    Where shownDisplayed in Requirements/Limits column (e.g., 'ST' or 'ST NSO')
    Dosage abbreviation key — mappings of short codes to dosage forms
    AEROAerosol (dosage abbreviation mapping)
    INJInjectable (dosage abbreviation mapping)
    LIQD / SUSP / SUSP RECONLiquid / Suspension / Suspension Reconstituted (dosage abbreviation mapping)
    CREA / OINT / LOTNCream / Ointment / Lotion (dosage abbreviation mapping)
    QL(...) — definition of quantity limit notation
    QL(...) notationIndicates a quantity limit with amount and period, e.g., QL(30 GM per 30 days)
    Units and periodsMay show units (EA, GM, ML) and period (per 30 days, per 28 days, per 365 days)
    EnforcementClaims exceeding QL require override or may be denied
    PA — prior authorization explained as a requirement marker
    PA explainedPrior Authorization requires approval from BlueCross Total before the prescription is filled when 'PA' is indicated
    ConsequenceWithout PA the plan may not cover the drug
    Where to findSee Requirements/Limits column in the formulary listings
    NDS — noted but not defined in excerpt
    NDS usage noteNDS appears as a Requirements/Limits flag in the table but is not fully defined in this excerpt; it denotes Non‑Extended Day Supply
    EffectIndicates the drug is not available for extended days' supply fills
    Where shownCommonly used next to opioid formulations in the Requirements/Limits key
    Requirements/Limits Key — table header indicating fields
    Requirements/Limits headerTable header field that lists drug name, dosage form, Drug Tier, and any Requirements/Limits such as QL, PA, ST
    PurposeIndicates the specific coverage controls applicable to each listed product
    ReferenceProviders should consult this field to determine PA/QL/ST requirements
    PA NSO — as used in the table
    PA NSOPrior Authorization with Non‑Standard Ordering (PA NSO) as used in the table
    UsageApplied to many specialty/oncology agents in Requirements/Limits column
    EffectIndicates PA plus nonstandard ordering constraints may apply
    QL — quantity limit definition
    QL definitionQuantity Limit (e.g., QL(91 EA per 91 days) indicates maximum units dispensed per specified period)
    DisplayShown adjacent to product entries in Requirements/Limits column
    ExamplesUnits use EA (each), GM (grams), ML (milliliters), etc.
    PA / PA NSO — prior authorization with NSO note
    PA / PA NSOPA = Prior Authorization; PA NSO indicates prior authorization with non‑standard ordering as noted in the formulary
    Where usedAppears widely for depot and specialty injections (e.g., Lupron Depot, Firmagon)
    Provider actionSubmit PA documentation per plan rules when shown
    Note

    Step Therapy Rules & Identified Products

    ScopePolicy
    When 'ST' or 'ST NSO' appears in the Requirements/Limits columnStep therapy applies; 'ST NSO' is defined as 'Step Therapy for New Starts Only' in the Requirements/Limits key and indicates step therapy applies to new starts only.
    Example productsRequirement
    BRIVIACT (solution and tablet), EPIDIOLEX (solution)Listed with 'PA NSO' in the Requirements/Limits column — prior authorization (PA) with NSO designation is required and may imply step or specialty review prior to coverage.
    ProductFlag shown
    AUVELITY tablet extended release 105 mg/45 mgRequirements/Limits = QL(60 EA per 30 days); ST NSO (step therapy for new starts only).
    EXXUA titration pack and tabletsRequirements/Limits include ST NSO on titration and tablet presentations (some strengths show QL and ST NSO).
    EMSAM transdermal patch (MAOI) — general class reference'ST NSO' is listed in the Requirements/Limits key as a step-therapy indicator for new starts (EMSAM listed among antidepressant/patch products in the same section).
    ItemRequirements/Limits
    FETZIMA titration pack and FETZIMA capsulesRequirements/Limits = QL(30 EA per 30 days); ST NSO — step therapy applies for new starts as indicated in the key.
    ExamplesStep therapy flag
    RYTARY capsule extended releaseRequirements/Limits = ST (step therapy) as shown in the formulary extract.
    FANAPT titration packs (A/B/C) and FANAPT tabletsRequirements/Limits = QL(...) and ST NSO on titration packs and ST NSO on some FANAPT entries indicating step therapy for new starts.
    INVEGA HAFYERA injectionRequirements/Limits = ST NSO — step therapy for new starts only as listed in the Requirements/Limits column.
    Product examplesInterpretation
    NEULASTA, PROCRIT, UDENYCA (selected high-cost injectable/supportive care agents)These products are designated 'PA' in the Requirements/Limits column; the PA designation may reflect specialty handling or program review rather than an explicit step-therapy edit in the excerpt.
    AgentsControls shown
    PRALUENT and REPATHA (PCSK9 inhibitors)Requirements/Limits list QL values (e.g., QL(2 ML per 28 days) for PRALUENT; QL(3 ML or 7 ML per 28 days) for REPATHA) and 'PA' — no explicit step sequence is provided in the cited excerpts.
    ProductStep therapy flag
    Diclofenac sodium gel 3%Requirements/Limits = QL(300 GM per 30 days); ST — listed with an explicit 'ST' step therapy flag.
    RELISTOR injection and tablet presentationsRELISTOR entries appear in the same section and are described in the brief as having 'ST' flags (diclofenac/RELISTOR examples cited).
    ContextPolicy note
    Higher‑tier agents and specialty products (examples in extract include various Tier 5 specialty drugs)Many higher‑tier agents are designated 'PA' in the Requirements/Limits column indicating prior authorization is required before coverage; the excerpt does not show explicit step edits for these agents.

    Documented Quantity Limits (Selected Examples)

    Background & Scope

    Biological products are complex and may have biosimilar alternatives. The formulary distinguishes between original biological products and biosimilars; where a biosimilar is designated as interchangeable, substitution may occur consistent with state law and plan policy. Providers should consult the formulary introduction for substitution rules and any preferences the plan has for biosimilars versus reference biologics.